Incyte Corporation
Experimental Station
Route 141 & Henry Clay Road Building E336
Wilmington,
DE 19880
Phone: 302-498-6700
Fax: 302-425-2750
Web Site: http://www.incyte.com
| REUTERS ABRIDGED BUSINESS SUMMARY | |
| Incyte Corporation, a drug discovery and development company, focuses on developing proprietary small molecule drugs to treat oncology, inflammation, and diabetes. The companys products include INCB18424 (Oral), which is in Phase IIa clinical trials for the treatment of myelofibrosis, polycythemia vera/essential thrombocythemia, rheumatoid arthritis, refractory prostate cancer, and multiple myeloma; INCB18424 (Topical), which is in a Phase IIb clinical trial for the treatment of Psoriasis; and INCB28050, which is in Phase I trial for the treatment of rheumatoid arthritis. Its products also include INCB13739, which is in a Phase IIb clinical trial for the treatment of Type 2 Diabetes; and INCB20817, which is in a Phase I trial for the treatment of Type 2 Diabetes. In addition, the companys products include INCB7839 in Phase IIa clinical trial for the treatment of solid tumors, and Phase II clinical trial for the treatment of breast cancer; INCB19602 in Phase IIa clinical trial for the treatment of Type 2 Diabetes; INCB8696 in Phase I clinical trial for the treatment of multiple sclerosis; INCB9471 in Phase II clinical trial for the treatment of HIV; and INCB15050 in Phase I clinical trial for the treatment of HIV. Further, its Investigational New Drug application cleared products include INCB28060 for the treatment of solid cancers and INCB24360 for the treatment of Oncology. The company operates in the United States, Canada, Germany, Sweden, and the United Kingdom. It has a collaborative research and license agreements with Pfizer, Inc. and ArtusLabs Inc. Incyte Corporation was founded in 1991 and is headquartered in Wilmington, Delaware. |
|
| Key Statistics | More from Reuters
Expanded Business Description |
| |
| REUTERS ABRIDGED FINANCIAL SUMMARY | |
| | Pay | Exercised | Dr. Paul A. Friedman M.D., 67
Chief Exec. Officer, Pres, Director, Member of Non-Management Stock Option Committee and Member of Fin. Committee |
N/A
| N/A | Mr. Roy A. Whitfield , 56
Co-Founder, Director and Member of Audit Committee |
$
32.00K | N/A | Mr. David C. Hastings CPA, 48
Chief Financial Officer and Exec. VP |
N/A
| N/A | Dr. Brian W. Metcalf Ph.D., 64
Chief Drug Discovery Scientist and Exec. VP |
N/A
| N/A | Ms. Patricia A. Schreck , 56
Exec. VP, Sec. and Gen. Counsel |
$
415.00K | N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
Reuters offers more in-depth
